Demographic characteristics, thromboembolism risk, and treatment patterns for patients with cold agglutinin disease in Japan.


Journal

International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 03 03 2020
accepted: 29 05 2020
revised: 30 04 2020
pubmed: 2 7 2020
medline: 11 11 2020
entrez: 2 7 2020
Statut: ppublish

Résumé

Cold agglutinin disease (CAD) is a rare, complement-mediated autoimmune hemolytic anemia. Patients with CAD in the United States and Europe have an increased incidence of thromboembolism (TE), but comparable information for patients in other regions is lacking. Thus, we examined TE risk for patients with CAD in Japan. Patients with CAD (at least three claims with a CAD diagnosis; Japanese Disease Code 2830009) and non-CAD controls were retrospectively identified (2008-2017) from a large hospital-based administrative claims dataset in Japan. Cohorts were compared using conditional logistic regression. We identified 344 patients with CAD (53.2% female; mean age: 66.8 years) and 3440 matched controls. Patients with CAD had higher TE rates than controls (34.9% vs. 17.9%; P < 0.0001). Both arterial and venous TEs were increased in the CAD group when compared with the control group (25.0% vs. 4.6% and 8.4% vs. 4.0%, respectively; both P < 0.0001). Most arterial TEs in the CAD cohort (87.2%) were myocardial infarctions. The overall odds ratio for TE development in CAD was 2.81 (95% confidence interval 2.18-3.61). CAD in Japan is characterized by an increased risk of TE. The rate of arterial TEs was particularly high in this patient population.

Identifiants

pubmed: 32608010
doi: 10.1007/s12185-020-02899-6
pii: 10.1007/s12185-020-02899-6
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

307-315

Auteurs

Toyomi Kamesaki (T)

Division of Support in Community Medicine, Center for Community Medicine, Regional Medical Center, Center for Regional Medical Care, Jichi Medical University, 3311 - 1 Yakushiji Shimotsuke-shi, Tochigi, Japan. kmskt@jicji.ac.jp.

Jun-Ichi Nishimura (JI)

Osaka University, Osaka, Japan.

Hideho Wada (H)

Kawasaki Medical School, Kurashiki, Japan.

Eric Yu (E)

IQVIA Solutions K.K., Tokyo, Japan.

Elisa Tsao (E)

Sanofi, Waltham, MA, USA.

Jaime Morales (J)

Sanofi, Waltham, MA, USA.

Yuzuru Kanakura (Y)

Osaka University, Osaka, Japan.
Sumitomo Hospital, Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH